"Dec. 18, 2012 -- People who can't get their high blood pressure down with drugs may be helped by a new procedure that deactivates overactive nerves in the kidneys, a small study shows.
The procedure is already available in Europe and "...
Adult Patients: Fenoldopam causes a dose-related fall in blood pressure and increase in heart rate (see PRECAUTIONS, Tachycardia, and Hypotension). In controlled clinical studies of severe hypertension in patients with end-organ damage, 3% (4/137) of patients withdrew because of excessive falls in blood pressure. Increased heart rate could, in theory, lead to ischemic cardiac events or worsened heart failure, although these events have not been observed. The most common events reported as associated with fenoldopam use are headache, cutaneous dilation (flushing), nausea, and hypotension, each reported in more than 5% of patients.
Adverse reactions in controlled trials in hypertensive adult patients
Adverse events occurring more than once in any dosing group (once if potentially important or plausibly drug-related) in the fixed-dose constant-infusion studies are presented in the following Table by infusion-rate group. There was no clear dose relationship, except possibly for headache, nausea, flushing.
Table 4: ADVERSE EVENTS* FROM FIXED-DOSE INFUSION STUDIES
BY DOSAGE GROUP
|Body System||Fenoldopam Dosage (mcg/kg/min) (Adults)|
|Injection site reaction||0||1||3||0||3||2|
|Cardiovascular||ST-T abnormalities (primarily T-wave inversion)||0||2||4||0||1||0|
|Metabolic and Nutritional||Increased creatinine**||0||0||2||0||0||0|
|Skin and Appendages||Sweating||0||0||0||1||1||2|
|Urogenital||Urinary tract infection||0||2||0||1||0||0|
|*Includes events reported by 2 or more patients receiving
fenoldopam treatment across all dose groups.
**Investigator defined; no protocol definition.
Adverse effects in overall database
The adverse event incidences listed below are based on observations of over 1,000 fenoldopam treated adult patients and not listed in Table 4 above.
Events reported with a frequency between 0.5-5% in patients treated with IV fenoldopam
Metabolic: elevated BUN, elevated serum glucose, elevated transaminase, elevated LDH
General Body: non-specific chest pain, pyrexia
Hematologic/Lymphatic: leukocytosis, bleeding
Respiratory: Dyspnea, upper respiratory disorder
Musculoskeletal: limb cramp
Pediatric Patients: In pediatric patients, the most common adverse events reported during short term administration in controlled trials (30 minutes) were hypotension and tachycardia. However, because of the short exposure, there is limited experience with defining adverse events in children. The long-term effects of fenoldopam on growth and development have not been studied.
Read the Corlopam (fenoldopam mesylate) Side Effects Center for a complete guide to possible side effects
General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin. There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).
Last reviewed on RxList: 10/24/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Corlopam Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.